ORIC Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    54930033FJRNEYBW0L25
    ISIN
    US68622P1093 (ORIC)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    49 / 100
    Even with peer group:
    49 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Read full profile

    Fundamentals

    Net revenue
    €454.62K
    Gross margin
    41.8%
    EBIT
    -€127.66M
    EBIT margin
    -28,080.7%
    Net income
    -€117.07M
    Net margin
    -25,750.3%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€129.38M +10.5%
    €2.64M -€141.10M +9.1%
    €21.84M +725.8% -€155.19M +10.0%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Andreas Halvorsen 6.6M $36.68M +2.1M Buy

    Earnings Calls

    Latest earnings call: March 21, 2022 (Q4 2021)

    Add to watchlist

    Notifications